"Cell Therapy" in Patent Application Approval Process (USPTO 20240325567).

The patent application discussed in the article focuses on the development of a method for modifying immune cells, particularly macrophages, using lentiviral vectors to express therapeutic proteins for potential gene therapy applications. The inventors aim to address challenges in gene therapy for lung diseases by targeting macrophages as a delivery vehicle for sustained transgenic protein expression. The method involves transducing immune cells with lentiviral vectors pseudotyped with specific proteins to express therapeutic proteins, offering potential treatments for conditions like Cystic Fibrosis, Alpha 1-antitrypsin Deficiency, and other lung-related disorders. [Extracted from the article]